Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
- 30 April 2010
- journal article
- research article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 176 (4), 1639-1647
- https://doi.org/10.2353/ajpath.2010.090711
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A StatusJournal of Clinical Oncology, 2009
- Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 TrialsClinical Cancer Research, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Layered Peptide Array for Multiplex ImmunohistochemistryThe Journal of Molecular Diagnostics, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- p27 Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant ChemotherapyJNCI Journal of the National Cancer Institute, 2006
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Progesterone Receptors as a Prognostic Factor in Stage II Breast CancerNew England Journal of Medicine, 1983